Effectiveness of blood pressure lowering: evidence-based comparisons between men and women

References

• Rodgers A, Ezzati M, Vander Hoorn S, Lopez A, Lin R, Murray C. Distribution of major health risks: findings from the Global Burden of Disease study. PLoS Med.1, e27 (2004).
   PubMedGoogle Scholar
• Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation119(3), e21–e181 (2009).
   PubMed Web of Science ®Google Scholar
• Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J. Hypertens.24, 423–430 (2006).
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet360, 1903–1913 (2002).
   PubMed Web of Science ®Google Scholar
• Woodward M. Epidemiology: Study Design and Data Analysis (2nd Edition). Chapman and Hall/CRC Press, Boca Raton, FL, USA (2005).
   Google Scholar
• Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular diseases in the Asia–Pacific region. J. Hypertens.21(4), 707–716 (2003).
   PubMed Web of Science ®Google Scholar
• Asia Pacific Cohort Studies Collaboration. Does sex matter in the associations between classical risk factors and fatal coronary heart disease? J. Women’s Health14, 820–828 (2005).
   PubMed Web of Science ®Google Scholar
• Quan A, Kerlikowske K, Gueffiyer F, Boissel J-P; INDANA Investigators. Efficacy of treating hypertension in women. J. Gen. Intern. Med.14, 718–729 (1999).
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA288, 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• Gueffiyer F, Boutitie F, Boissel J-P et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomised controlled trials. Ann. Intern. Med.126, 761–767 (1997).
   PubMed Web of Science ®Google Scholar
• WHO-International Society of Hypertension Blood Pressure Lowering Treatment Trialists’ Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure lowering treatments. J. Hypertens.16, 127–137 (1998).
   PubMed Web of Science ®Google Scholar
• Blood Pressure Lowering Treatment Trialists’ Collaboration. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J.29, 2669–2680 (2008).
   PubMed Web of Science ®Google Scholar
• Brenner B, Cooper M, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med.345, 861–869 (2001).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux R, Kjeldsen S et al.; LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet359, 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers S, Dahlof B, Elmfeldt D, Julius S; for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) Randomised trial. Lancet351, 1755–1762 (1998).
   PubMed Web of Science ®Google Scholar
• National Intervention Cooperative Study in Elderly Hypertensives study group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension34, 1129–1133 (1999).
   PubMed Web of Science ®Google Scholar
• MacMahon S, Sharpe N, Gamble G et al.; PART-2 Collaborative Research Group. Randomised, placebo-controlled trial of the angiotensin converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive vascular disease. J. Am. Coll. Cardiol.36, 438–443 (2000).
   PubMed Web of Science ®Google Scholar
• Pitt B, Byington R, Furberg C et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation102, 1503–1510 (2000).
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet358, 1033–1041 (2001).
   PubMed Web of Science ®Google Scholar
• Teo K, Burton J, Buller C et al.; SCAT Investigators. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis. The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation102, 1748–1754 (2000).
   PubMed Web of Science ®Google Scholar
• Staessen J, Fagard R, Thijs L et al.; SYST-EUR Study Group. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension in Europe. Lancet350, 757–764 (1997).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 39. Br. Med. J.317, 713–720 (1998).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. Br. Med. J.317, 703–713 (1998).
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Agabiti-Rosei E, Dal Palu C, Leonetti G, Magnani B, Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomised treatment with either verapamil or chlorthalidone on intima-media thickness. J. Hypertens.16, 1667–1676 (1998).
   PubMed Web of Science ®Google Scholar
• HOPE (Heart Outcomes Prevention Evaluation) study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med.342, 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Pitt B, O’Neill B, Feldman R et al.; QUIET study group. The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am. J. Cardiol.87, 1058–1063 (2001).
   PubMed Web of Science ®Google Scholar
• Dens J, Desmet W, Coussement P et al. Usefulness of nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study). Am. J. Cardiol.87, 28–33 (2001).
   PubMed Web of Science ®Google Scholar
• Wright J, Bakris G, Green T et al.; African American Study of Kidney Disease and Hypertension study group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA288, 2421–2431 (2002).
   PubMed Web of Science ®Google Scholar
• Estacio R, Jeffers B, Hiatt W, Biggerstaff S, Gifford N, Schrier R. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N. Engl. J. Med.338, 645–652 (1998).
   PubMed Web of Science ®Google Scholar
• Schrier R, Estacio R, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive Type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int.61, 1086–1097 (2002).
   PubMed Web of Science ®Google Scholar
• Wing L, Reid C, Ryan P et al.; Second Australian National Blood Pressure study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med.348, 583–592 (2003).
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm L, Niskanen L et al.; Captopril Prevention Project (CAPPP) study group. Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet353, 611–616 (1999).
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm L, Ekbom T et al.; STOP-Hypertension-2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet354, 1751–1756 (1999).
   PubMed Web of Science ®Google Scholar
• Black H, Elliot W, Grandits G, Grambsch P, Lucente T, White W; CONVINCE research group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial. JAMA289, 2073–2082 (2003).
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Bond M, Hennig M et al.; ELSA investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Circulation106, 2422–2427 (2002).
   PubMed Web of Science ®Google Scholar
• Brown M, Palmer C, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet356, 366–372 (2000).
   PubMed Web of Science ®Google Scholar
• Hansson L, Hedner T, Lund-Johansen P et al.; NORDIL study group. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet356, 359–365 (2000).
   PubMed Web of Science ®Google Scholar
• Malacco E, Gnemmi A, Romagnoli A, Coppini A; SHELL study group. Systolic hypertension in the elderly: long-term lacidipine treatment. J. Cardiovasc. Pharmacol.23(Suppl. 5), S62–S66 (1994).
   Google Scholar
• Yui Y, Sumiyoshi T, Kodama K et al.; Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) study group. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens. Res.27, 181–191 (2004).
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Fassi A, Ilieva A et al.; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) investigators. Preventing microalbuminuria in Type 2 diabetes. N. Engl. J. Med.351, 1941–1951 (2004).
   PubMed Web of Science ®Google Scholar
• Marre M, Lievre M, Chatellier G, Mann J, Passa P, Menard J; on behalf of the DIABHYCAR study investigators. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with Type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). Br. Med. J.328, 495 (2004).
   PubMed Web of Science ®Google Scholar
• The European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet362, 782–788 (2003).
   PubMed Web of Science ®Google Scholar
• Asselbergs F, Diercks G, Hillege H et al.; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation110, 2809–2816 (2004).
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kulschewski A et al.; MOSES study group. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Stroke36, 1218–1226 (2005).
   PubMed Web of Science ®Google Scholar
• Pepine C, Handberg E, Cooper-DeHoff R et al.; INVEST investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil–Trandolapril Study (INVEST): a randomized controlled trial. JAMA290, 2805–2816 (2003).
   PubMed Web of Science ®Google Scholar
• Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus; results of propsectively designed overviews. Arch. Intern. Med.165, 1410–1419 (2005).
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Ninomiya T et al.; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. Br. Med. J.336, 1121–1123 (2008).
   PubMed Web of Science ®Google Scholar
• Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokoski E, Amouyel P; WHO MONICA (monitoring trends and determinants in cardiovascular disease) project. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet353, 1547–1557 (1999).
   PubMed Web of Science ®Google Scholar
• Safar M, Smulyan H. Hypertension in women. Am. J. Hypertens.17, 82–87 (2004).
   PubMed Web of Science ®Google Scholar
• Ong K, Tso A, Lam K, Cheung B. Gender difference in blood pressure control and cardiovascular risk factors in Americans with diagnosed hypertension. Hypertension51, 1142–1148 (2008).
   PubMed Web of Science ®Google Scholar
• Mosca L, Linfante A, Benjamin E et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation111, 499–510 (2005).
   PubMed Web of Science ®Google Scholar
• Keyhani S, Scobie JV, Hebert PL, McLaughlin MA. Gender disparities in blood pressure control and cardiovascular care in a national sample of ambulatory care visits. Hypertension51, 1149–1155 (2008).
   PubMed Web of Science ®Google Scholar
• Gu Q, Burt VL, Paulose-Ram R, Dillon CF. Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey 1999–2004. Am. J. Hypertens.21, 789–798 (2008).
   PubMed Web of Science ®Google Scholar
• Di Martino M, Veronesi C, Degli Esposti L et al. Adherence to antihypertensive drug treatment and blood pressure control: a real practice analysis in Italy. J. Hum. Hypertens.22, 51–53 (2008).
   PubMed Web of Science ®Google Scholar
• Mosca L, Ferris A, Fabunmi R, Robertson RM; American Heart Association. Tracking women’s awareness of heart disease: an American Heart Association national study. Circulation109, 573–579 (2004).
   PubMed Web of Science ®Google Scholar
• Nissinen A, Kastarinen M, Tuomilehto J. Community control of hypertension – experiences from Finland. J. Hum. Hypertens.18, 553–556 (2004).
   PubMed Web of Science ®Google Scholar
• Ninios I, Ninios V, Lazaridou F, Dimitriadis K, Kerasidou O, Louridas G. Gender-specific differences in hypertension prevalence, treatment, control, and associated conditions among the elderly: data from a Greek population. Clin. Exp. Hypertens.30, 327–337 (2008).
   PubMed Web of Science ®Google Scholar
• Wu Y, Huxley R, Li L et al.; for the China NNHS Working Group. Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002. Circulation118, 2679–2686 (2008).
   PubMed Web of Science ®Google Scholar
• Stramba-Badiale M, Fox KM, Priori SG et al. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur. Heart J.27, 994–1005 (2006).
   PubMed Web of Science ®Google Scholar